Bristol-Myers Squibb Company
BMYBristol-Myers Squibb lives and dies by its ability to invent, acquire, and defend high-value drugs over decades.
Because in pharmaceuticals, a few molecules can shape billions in profit for 20 years.
Business Model
Patent-protected medicines
It discovers, develops, and sells branded drugs that are protected from generic competition for years.
Economic Engine
High cash generation
Gross margins of 67.6% and free cash flow far above net income power the model.
Long-Term Lens
Pipeline replacement
The key question is whether new drugs can offset expiring patents over the next decade.
BinaPrint Snapshot
Style
Blend
Fitness
Mixed
Updated Mar 8, 2026
On this page
Company Story
How do Bristol-Myers Squibb Company's business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A cash-rich pharmaceutical heavyweight whose future hinges on replacing aging blockbusters with a durable next generation of therapies.”
What does Bristol-Myers Squibb Company actually do?
Bristol-Myers Squibb researches, develops, and sells prescription medicines, mainly for cancer, heart disease, and immune disorders.
- Invests billions each year in drug research and clinical trials
- Sells patented medicines to hospitals, clinics, and pharmacies worldwide
- Focuses heavily on oncology and specialty treatments
Why it matters
Science drives revenue
If the science works and wins approval, a single successful drug can generate billions in annual sales for many years.
How does Bristol-Myers Squibb Company make money?
It earns revenue by selling branded drugs at premium prices while they are protected by patents.
- Gross margin of 67.6%, showing strong pricing power
- Operating margin of 26.3%, leaving room to fund research and marketing
- Free cash flow equal to 26.7% of revenue, converting profits into real cash
Economic clue
Cash exceeds accounting profit
Free cash flow is 1.82 times net income, suggesting earnings are backed by real cash.
Why do long-term investors keep Bristol-Myers Squibb Company on the radar?
Demand for cancer and specialty drugs is tied to aging populations and ongoing medical innovation.
- Cancer rates tend to rise as populations age
- New biologic drugs can command premium prices for years
- Scale and global reach support large research budgets
Investor takeaway
Demographics are a tailwind
An aging global population creates steady long-term demand for advanced therapies.
Based on company financial statements.
What Could Change The Story
- Drifting would move the profile toward Anchor.
- Strengthening would move the profile toward Anchor.
Benchmark Comparison
How has Bristol-Myers Squibb Company performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$997.68
-0.2% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| BMY | -0.2% | $997.68 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Bristol-Myers Squibb Company
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to long-term growth in cancer and specialty medicines
- A company with high gross margins and strong cash generation
- A business tied to demographic trends rather than consumer fads
Be Careful If You Expect
- Steady revenue growth every single year
- Low earnings volatility, drug profits can swing with patent cycles
- Minimal regulatory or political risk
What To Watch Over Time
- Success rate of late-stage clinical trials
- Revenue mix from newer drugs versus aging blockbusters
- Research and acquisition spending discipline
BinaPrint Position
Where does Bristol-Myers Squibb Company sit on the BinaPrint map right now?
Test whether business quality and financial profile match the company's stated narrative.
Advanced BinaPrint details
Open the axes, investor fit, and risk framing behind this profile.
Key Metrics
Which metrics matter most for Bristol-Myers Squibb Company right now?
Three durable business metrics that matter more than day-to-day price moves.
1.0% average annual growth over 5 years
2.4% average annual growth over 5 years
67.6% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 1.0% average annual growth over 5 years | Shows that sales have been largely flat, reflecting patent cycles rather than steady expansion. |
| EPS Growth | 2.4% average annual growth over 5 years | Indicates modest long-term profit growth with significant volatility. |
| Margin Quality | 67.6% gross margin | High margins signal strong pricing power from patented medicines. |
Based on company financial statements.
Fundamentals
What do Bristol-Myers Squibb Company's fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
12.4% ROIC
67.6% gross margin
26.7% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 12.4% ROIC | The business is currently showing fair capital efficiency. |
| Profitability | 67.6% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 26.7% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Bristol-Myers Squibb Company?
Company-specific questions readers often ask about Bristol-Myers Squibb Company.
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
It develops and sells patented prescription medicines, mainly focused on cancer and other serious diseases.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Aging populations globally increase demand for cancer and cardiovascular treatments, supporting steady long-term need for its core products.
Patent protection allows temporary monopolies, enabling gross margins near 68% and strong cash generation while exclusivity lasts.
Scale enables funding of expensive late-stage trials that smaller rivals cannot easily replicate, creating barriers to entry.
Strong cash conversion, with free cash flow at 1.82 times net income, provides flexibility to invest through downturns or patent cliffs.
Bear case
What can break
Patent expirations on major drugs could open the door to generic competition, rapidly eroding billions in annual revenue.
Drug pricing reform in the United States or other major markets could cap prices and compress margins across the portfolio.
Scientific failure in late-stage trials could leave gaps in the pipeline, stalling growth for years.
Biotechnology disruption, such as gene therapies or personalized treatments from newer players, could shift profits away from traditional drug makers.
Risk Radar
Key Risks
Where downside pressure can build.
Patent concentration risk, loss of exclusivity on a single blockbuster drug could remove billions in annual revenue.
Regulatory pricing pressure in the United States, its largest market, could reduce gross margin from 67.6% over time.
Pipeline failure risk, multi-year research spending may not translate into approved products.
Pressure points
Concentration risk
Large pharmaceutical companies often rely heavily on a few blockbuster drugs. If a small number of products represent a significant share of revenue, the expiration of their patents could materially reduce total sales within a few years.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $60.29
- Daily move
- -0.74%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.